ACCOUNTS - Final Accounts

Registered number: 05414917

LANG THORACIC LIMITED

UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

For the Year Ended 30 June 2025

LANG THORACIC LIMITED

Registered number: 05414917

STATEMENT OF FINANCIAL POSITION

As at 30 June 2025

		2025		2024
Note		£		£

Fixed assets
Tangible assets	3		730		730
			730		730
Current assets
Debtors: amounts falling due within one year	4	3,547		50,236
Cash at bank and in hand	5	121		3,959
		3,668		54,195
Creditors: amounts falling due within one year	6	(20,986)		(45,351)
Net current (liabilities)/assets			(17,318)		8,844
Total assets less current liabilities			(16,588)		9,574

Net (liabilities)/assets			(16,588)		9,574

Capital and reserves
Called up share capital	7	100	100
Profit and loss account	8	(16,688)	9,474
		(16,588)	9,574

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

Page 1

LANG THORACIC LIMITED

Registered number: 05414917

STATEMENT OF FINANCIAL POSITION (CONTINUED)

As at 30 June 2025

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 15 June 2026.

Loic Lang-Lazdunski

Director

The notes on pages 3 to 7 form part of these financial statements.

Page 2

LANG THORACIC LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the Year Ended 30 June 2025

1.Accounting policies

1.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A) of the Companies Act 2006.

The following principal accounting policies have been applied:

1.2

Interest income

Interest income is recognised in profit or loss using the effective interest method.

1.3

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

1.4

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

1.5

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Office equipment

20% straight line basis

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

Page 3

LANG THORACIC LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the Year Ended 30 June 2025

1.Accounting policies (continued)

1.6

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

1.7

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

2.	Judgments in applying accounting policies and key sources of estimation uncertainty

In the application of the company's accounting policies management is required to make judgements, estimates and assumptions about the carrying value of assets and liabilities that are not readily ascertainable from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual outcomes may differ from these estimates.
The estimates and underlying assumptions are reviewed on an continuing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised.
The key areas of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements are described below:
Prepayments & accrued expenditure
The company includes a provision for invoices which are yet to be received from and amounts paid in advance to suppliers. These provisions are estimated based upon the expected values of the invoices which are issued and services received following the period end.

Page 4

LANG THORACIC LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the Year Ended 30 June 2025

3.	Tangible fixed assets

		Office equipment
		£
	Cost or valuation
	At 1 July 2024	912
	At 30 June 2025	912
	Depreciation
	At 1 July 2024	182
	At 30 June 2025	182
	Net book value
	At 30 June 2025	730
	At 30 June 2024	730

Page 5

LANG THORACIC LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the Year Ended 30 June 2025

Debtors

					2025	2024
					£	£


Other debtors	3,547	50,236
	3,547	50,236

5.	Cash and cash equivalents
		2025	2024
		£	£

Cash at bank and in hand	121	3,959
	121	3,959

6.	Creditors: Amounts falling due within one year
		2025	2024
		£	£

Bank loans	19,425	39,690
Other creditors	-	4,099
Accruals and deferred income	1,561	1,562
	20,986	45,351

7.	Share capital
		2025	2024
		£	£

Allotted, called up and fully paid

100 (2024 - 100) Ordinary shares of £1.00 each	100	100

Reserves

Profit & loss account

The profit and loss reserve is fully distributable.

Page 6

LANG THORACIC LIMITED

NOTES TO THE FINANCIAL STATEMENTS

For the Year Ended 30 June 2025

9.	Related party transactions
	At the balance sheet date the company owed £12,616 (2024 - £2,978) to Mr L Lang-Lazdunski, a director. Interest was charged at 2% on outstanding balances throughout the year. At the balance sheet date the company owed £nil (2024 - £229) to Mrs A Lang, a director and majority shareholder. Interest was charged at 2% on outstanding balances throughout the year.

Page 7